NEEDHAM, Mass.--(BUSINESS WIRE)--Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that the underwriters of its previously announced public offering of common stock have exercised in full their overallotment option to purchase an additional 1,575,000 shares of common stock at the public offering price of $3.85 per share, less underwriting discounts and commissions. Proceeds from the exercise of the option will be approximately $5.7 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. The closing of the overallotment option exercise is expected to occur on March 19, 2012, subject to customary closing conditions.
